Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space. Viking reported positive results for its new obesity pill, its breakthrough overshadowed not too soon after by other names in the space.

Julie Hyman and Josh Lipton report on the latest for Viking Therapeutics' phase 1 trial results and the latest out of the ObesityWeek conference in San Antonio, Texas.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

This post was written by Luke Carberry Mogan.